Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock

Recruiting N/A Interventional Study
Cardiogenic Shock Mitral Regurgitation
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
144 (estimated)
Sponsor
Ottawa Heart Institute Research Corporation · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Mitral regurgitation may be seen in the setting of cardiogenic shock. Transcatheter edge-to-edge repair (TEER) has been shown to improve outcomes in patients with chronic heart failure. Observational studies suggest improvements in clinical outcomes in patients with mitral regurgitation in the setting of cardiogenic shock; however, there remains a lack of randomized clinical data to support the us…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Participants or substitute decision maker is able and willing to provide written informed consent 2. Age ≥ 18 years 3. SCAI stage C or D cardiogenic shock with persistent inotrope/vasopressor/non-durable mechanical support or unable to wean ventilatory support due to pulmonar…
Contacts

Benjamin Hibbert, MD PhD

613-696-7115

bhibbert@ottawaheart.ca

CONTACT

Pietro Di Santo, MD

613-696-7000

pdisanto@ottawaheart.ca

CONTACT